Method of preventing cochlear disease, disorder or condition using (+)-azasetron

Abstract

Disclosed is a method for treating ear disorders, including the administration of (+)-azasetron, or a pharmaceutically acceptable salt and/or solvate thereof.

1 . A method of prevention of a cochlear disease, disorder or condition in a subject in need thereof, wherein said method comprises the administration to the subject of a composition comprising (+)-azasetron, of Formula (R)-I: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt and/or solvate thereof, 
         and at least one pharmaceutically acceptable excipient. 
       
     
     
         2 . The method according to  claim 1 , wherein the composition comprises at least a 90:10 w/w mixture of (+)-azasetron of Formula (R)-I:(−)-azasetron, or pharmaceutically acceptable salts and/or solvates thereof. 
     
     
         3 . The method according to  claim 1 , wherein the pharmaceutically acceptable salt of (+)-azasetron of Formula (R)-I is selected from the group consisting of: (+)-azasetron besylate, (+)-azasetron malate, and (+)-azasetron hydrochloride. 
     
     
         4 . The method according to  claim 1 , wherein the composition is administered at a dose ranging from about 0.01 mg to about 100 mg. 
     
     
         5 . The method according to  claim 1 , wherein the composition is administered at a dose ranging from about 20 to about 100 mg of free-base equivalent per day. 
     
     
         6 . The method according to  claim 1 , wherein the composition is administered systemically. 
     
     
         7 . The method according to  claim 1 , wherein the composition is administered orally. 
     
     
         8 . The method according to  claim 1 , wherein the composition is administered locally. 
     
     
         9 . The method according to  claim 1 , wherein the cochlear disease, disorder or condition is sensorineural hearing loss, cochlear ototoxicity, cochlear excitotoxic-inducing occurrence, cochlear hyperacusis, or cochlear tinnitus. 
     
     
         10 . The method according to  claim 1 , wherein the cochlear disease, disorder or condition is ototoxic compound-induced hearing loss. 
     
     
         11 . The method according to  claim 1 , wherein the cochlear disease, disorder or condition is platinum-induced hearing loss. 
     
     
         12 . The method according to  claim 1 , wherein the cochlear disease, disorder or condition is cisplatin-induced hearing loss. 
     
     
         13 . The method according to  claim 1 , wherein the subject is diagnosed with cancer. 
     
     
         14 . The method according to  claim 1 , wherein the subject is diagnosed with cancer and is awaiting the receipt of, or is receiving platinum-based chemotherapy. 
     
     
         15 . The method according to  claim 1 , wherein the subject is diagnosed with cancer and is awaiting the receipt of, or is receiving cisplatin, carboplatin, oxaliplatin or a combination thereof. 
     
     
         16 . The method according to  claim 1 , wherein the subject is diagnosed with cancer and wherein the composition is administered before, during and/or after platinum-based chemotherapy. 
     
     
         17 . The method according to  claim 1 , wherein the subject is diagnosed with cancer and wherein the composition is administered before, during and/or after cisplatin-, carboplatin- or oxaliplatin-based chemotherapy or a combination thereof. 
     
     
         18 . The method according to  claim 1 , wherein the cochlear disease, disorder or condition is sudden sensorineural hearing loss, noise-induced hearing loss, or age-related hearing loss. 
     
     
         19 . The method according to  claim 1 , wherein the composition is an immediate release composition or a sustained release composition. 
     
     
         20 . The method according to  claim 1 , wherein the composition is an orodispersible composition.